PMID- 36369228
OWN - NLM
STAT- MEDLINE
DCOM- 20230227
LR  - 20230427
IS  - 1532-2157 (Electronic)
IS  - 0748-7983 (Linking)
VI  - 49
IP  - 2
DP  - 2023 Feb
TI  - HER2 status based on breast cancer guidelines as a useful prognostic marker of T2 
      gallbladder cancer.
PG  - 392-398
LID - S0748-7983(22)00712-0 [pii]
LID - 10.1016/j.ejso.2022.10.020 [doi]
AB  - INTRODUCTION: T2 gallbladder cancer (GBC) is the only stage showing a survival 
      benefit after complete surgical resection, but recurrence rates remain high. 
      Although human epidermal growth factor receptor 2 (HER2) has emerged as a 
      therapeutic target, its role in T2 GBC remains unclear. This study investigated 
      the status and prognostic impact of HER2 expression on T2 GBC. MATERIALS AND 
      METHODS: HER2 expression and amplification were detected by immunohistochemistry 
      (IHC) and fluorescence in situ hybridization (FISH), respectively, in 90 patients 
      with T2 GBC who underwent radical cholecystectomy. We evaluated HER2 status 
      according to the breast and gastric cancer guidelines and analyzed the effect of 
      relevant prognostic factors on survival. RESULTS: HER2 positive status was 
      observed in 11.11% (10/90) and 8.89% (8/90) of cases based on gastric and breast 
      cancer guidelines, respectively. Poor differentiation and a higher level of 
      perineural invasion were independent prognostic factors of disease-free survival 
      (DFS). Old age, male sex, presence of lymph node metastasis, poor 
      differentiation, high levels of perineural invasion, and HER2 positivity based on 
      breast cancer guidelines were identified as independent prognostic factors of 
      overall survival (OS). Patients with HER2-positive T2 GBC according to breast 
      cancer guidelines had worse OS. CONCLUSIONS: HER2 positivity based on breast- but 
      not gastric-cancer guidelines was associated with poorer survival. These results 
      provide a criterion for the evaluation of HER2 and a rationale for therapeutic 
      strategies targeting HER2 in T2 GBC.
CI  - Copyright (c) 2022. Published by Elsevier Ltd.
FAU - Kwon, Chae Hwa
AU  - Kwon CH
AD  - Biomedical Research Institute, Pusan National University Hospital, Busan, South 
      Korea.
FAU - Seo, Hyung Il
AU  - Seo HI
AD  - Department of Surgery, Pusan National University School of Medicine and 
      Biomedical Research Institute, Pusan National University Hospital, Busan, South 
      Korea. Electronic address: seohi71@pusan.ac.kr.
FAU - Kim, Dong Uk
AU  - Kim DU
AD  - Department of Internal Medicine, Pusan National University School of Medicine and 
      Biomedical Research Institute, Pusan National University Hospital, Busan, South 
      Korea.
FAU - Han, Sung Yong
AU  - Han SY
AD  - Department of Internal Medicine, Pusan National University School of Medicine and 
      Biomedical Research Institute, Pusan National University Hospital, Busan, South 
      Korea.
FAU - Kim, Suk
AU  - Kim S
AD  - Department of Radiology, Pusan National University School of Medicine, Busan, 
      South Korea.
FAU - Lee, So Jeong
AU  - Lee SJ
AD  - Department of Pathology, Seegene Medical Foundation, Busan, South Korea.
FAU - Jeon, Da Ye
AU  - Jeon DY
AD  - Department of Internal Medicine, Pusan National University School of Medicine and 
      Biomedical Research Institute, Pusan National University Hospital, Busan, South 
      Korea.
LA  - eng
PT  - Journal Article
DEP - 20221102
PL  - England
TA  - Eur J Surg Oncol
JT  - European journal of surgical oncology : the journal of the European Society of 
      Surgical Oncology and the British Association of Surgical Oncology
JID - 8504356
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Humans
MH  - Male
MH  - *Gallbladder Neoplasms/pathology
MH  - *Breast Neoplasms/pathology
MH  - Prognosis
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Receptor, ErbB-2/metabolism
MH  - Disease-Free Survival
MH  - *Carcinoma in Situ
OTO - NOTNLM
OT  - Gallbladder cancer
OT  - HER2
OT  - HER2-Positivity criteria
OT  - Prognosis
OT  - Stage
COIS- Declaration of competing interest The authors declare no competing interests.
EDAT- 2022/11/12 06:00
MHDA- 2023/03/03 06:00
CRDT- 2022/11/11 23:59
PHST- 2022/09/05 00:00 [received]
PHST- 2022/10/23 00:00 [revised]
PHST- 2022/10/28 00:00 [accepted]
PHST- 2022/11/12 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
PHST- 2022/11/11 23:59 [entrez]
AID - S0748-7983(22)00712-0 [pii]
AID - 10.1016/j.ejso.2022.10.020 [doi]
PST - ppublish
SO  - Eur J Surg Oncol. 2023 Feb;49(2):392-398. doi: 10.1016/j.ejso.2022.10.020. Epub 
      2022 Nov 2.